304 related articles for article (PubMed ID: 30179227)
1. Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
Abdelaziz AO; Shousha HI; Said EM; Soliman ZA; Shehata AA; Nabil MM; Abdelmaksoud AH; Elbaz TM; Abdelsalam FM
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1384-1388. PubMed ID: 30179227
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
4. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
[TBL] [Abstract][Full Text] [Related]
5. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
[TBL] [Abstract][Full Text] [Related]
6. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
8. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
9. Computer-aided assessment of hepatic contour abnormalities as an imaging biomarker for the prediction of hepatocellular carcinoma development in patients with chronic hepatitis C.
Goshima S; Kanematsu M; Kondo H; Watanabe H; Noda Y; Fujita H; Bae KT
Eur J Radiol; 2015 May; 84(5):811-5. PubMed ID: 25650331
[TBL] [Abstract][Full Text] [Related]
10. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
11. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
12. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography.
Masuzaki R; Tateishi R; Yoshida H; Yoshida H; Sato S; Kato N; Kanai F; Sugioka Y; Ikeda H; Shiina S; Kawabe T; Omata M
J Clin Gastroenterol; 2008 Aug; 42(7):839-43. PubMed ID: 18668703
[TBL] [Abstract][Full Text] [Related]
13. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
14. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
[TBL] [Abstract][Full Text] [Related]
15. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
Shousha HI; Abdelaziz RA; Azab SM; Khairy M; Afifi SA; Mehrez MI; Eshra MA; Abdelrahim AY
J Med Virol; 2018 Jun; 90(6):1099-1105. PubMed ID: 29469217
[TBL] [Abstract][Full Text] [Related]
16. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
17. Significance of pSmad2/3 and Smad4 in hepatitis C virus-related liver fibrosis and hepatocellular carcinoma.
Moussa MM; Helal NS; Youssef MM
APMIS; 2018 Jun; 126(6):477-485. PubMed ID: 29924446
[TBL] [Abstract][Full Text] [Related]
18. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
19. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
Cai YJ; Dong JJ; Wang XD; Huang SS; Chen RC; Chen Y; Wang YQ; Song M; Chen YP; Li Z; Zhou MT; Shi KQ
J Viral Hepat; 2017 Nov; 24(11):1005-1015. PubMed ID: 28419755
[TBL] [Abstract][Full Text] [Related]
20. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
